10,516 Shares in Edwards Lifesciences Corporation $EW Purchased by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, HoldingsChannel reports. The fund acquired 10,516 shares of the medical research company’s stock, valued at approximately $951,000.

A number of other institutional investors also recently modified their holdings of EW. Rehmann Capital Advisory Group lifted its position in shares of Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares in the last quarter. McIlrath & Eck LLC increased its holdings in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 135 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after purchasing an additional 136 shares in the last quarter. Stephens Inc. AR raised its position in Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock worth $239,000 after purchasing an additional 144 shares during the last quarter. Finally, Composition Wealth LLC raised its position in Edwards Lifesciences by 1.6% in the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock worth $795,000 after purchasing an additional 147 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 25,570 shares of company stock worth $2,219,390 in the last ninety days. Company insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on EW. Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Barclays restated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Trading Up 1.5%

Shares of NYSE EW opened at $92.36 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market capitalization of $53.18 billion, a P/E ratio of 53.08, a P/E/G ratio of 2.29 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company’s 50 day simple moving average is $89.03 and its 200 day simple moving average is $84.57.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.